Evaxion Biotech A/S (EVAX) Competitors

Evaxion Biotech A/S (NASDAQ:EVAX) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership, risk and community ranking.

Do insiders and institutionals have more ownership in EVAX or ADXN?

11.0% of Evaxion Biotech A/S shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 41.6% of Evaxion Biotech A/S shares are owned by insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Is EVAX or ADXN more profitable?

Addex Therapeutics has a net margin of 850.30% compared to Evaxion Biotech A/S's net margin of -347.83%. Evaxion Biotech A/S's return on equity of 0.00% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion Biotech A/S	-347.83%	N/A	-79.40%
Addex Therapeutics	850.30%	-112.43%	-77.95%

Do analysts recommend EVAX or ADXN?

Evaxion Biotech A/S presently has a consensus target price of $10.00, indicating a potential upside of 663.94%. Addex Therapeutics has a consensus target price of $30.00, indicating a potential upside of 294.53%. Given Evaxion Biotech A/S's higher possible upside, equities analysts plainly believe Evaxion Biotech A/S is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion Biotech A/S	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Addex Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger valuation & earnings, EVAX or ADXN?

Addex Therapeutics has lower revenue, but higher earnings than Evaxion Biotech A/S. Addex Therapeutics is trading at a lower price-to-earnings ratio than Evaxion Biotech A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion Biotech A/S	$3.34M	0.55	-$22.12M	-$0.72	-1.82
Addex Therapeutics	$556.05K	14.50	-$11.76M	-$0.34	-22.36

Does the media favor EVAX or ADXN?

In the previous week, Addex Therapeutics had 3 more articles in the media than Evaxion Biotech A/S. MarketBeat recorded 4 mentions for Addex Therapeutics and 1 mentions for Evaxion Biotech A/S. Addex Therapeutics' average media sentiment score of -0.06 beat Evaxion Biotech A/S's score of -1.00 indicating that Addex Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Evaxion Biotech A/S	Negative
Addex Therapeutics	Neutral

Does the MarketBeat Community prefer EVAX or ADXN?

Evaxion Biotech A/S received 12 more outperform votes than Addex Therapeutics when rated by MarketBeat users. Likewise, 67.50% of users gave Evaxion Biotech A/S an outperform vote while only 51.72% of users gave Addex Therapeutics an outperform vote.

Company	Underperform	Outperform
Evaxion Biotech A/S	Outperform Votes 27 67.50%	Underperform Votes 13 32.50%
Addex Therapeutics	Outperform Votes 15 51.72%	Underperform Votes 14 48.28%

Which has more risk & volatility, EVAX or ADXN?

Evaxion Biotech A/S has a beta of -0.25, suggesting that its share price is 125% less volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.

Summary

Addex Therapeutics beats Evaxion Biotech A/S on 9 of the 17 factors compared between the two stocks.